CN101970404B - 制备作为hdac抑制剂的磺酰基吡咯的方法 - Google Patents

制备作为hdac抑制剂的磺酰基吡咯的方法 Download PDF

Info

Publication number
CN101970404B
CN101970404B CN2009801082773A CN200980108277A CN101970404B CN 101970404 B CN101970404 B CN 101970404B CN 2009801082773 A CN2009801082773 A CN 2009801082773A CN 200980108277 A CN200980108277 A CN 200980108277A CN 101970404 B CN101970404 B CN 101970404B
Authority
CN
China
Prior art keywords
alkyl
general formula
compound
morpholinyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009801082773A
Other languages
English (en)
Chinese (zh)
Other versions
CN101970404A (zh
Inventor
马蒂亚斯·穆勒
波恩德·穆勒
托马斯·梅艾尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4sc Corp
Original Assignee
4sc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4sc Corp filed Critical 4sc Corp
Publication of CN101970404A publication Critical patent/CN101970404A/zh
Application granted granted Critical
Publication of CN101970404B publication Critical patent/CN101970404B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
CN2009801082773A 2008-03-12 2009-03-11 制备作为hdac抑制剂的磺酰基吡咯的方法 Active CN101970404B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08004567.7 2008-03-12
EP08004567A EP2100878A1 (en) 2008-03-12 2008-03-12 Novel method for the production of sulphonylpyrroles as HDAC inhibitors
PCT/EP2009/052870 WO2009112529A1 (en) 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as hdac inhibitors

Publications (2)

Publication Number Publication Date
CN101970404A CN101970404A (zh) 2011-02-09
CN101970404B true CN101970404B (zh) 2013-05-08

Family

ID=39639400

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801082773A Active CN101970404B (zh) 2008-03-12 2009-03-11 制备作为hdac抑制剂的磺酰基吡咯的方法

Country Status (22)

Country Link
US (1) US8785659B2 (enExample)
EP (2) EP2100878A1 (enExample)
JP (1) JP5530939B2 (enExample)
KR (1) KR101571915B1 (enExample)
CN (1) CN101970404B (enExample)
AT (1) ATE519739T1 (enExample)
AU (1) AU2009224623C1 (enExample)
BR (1) BRPI0909752B8 (enExample)
CA (1) CA2719074C (enExample)
CY (1) CY1111994T1 (enExample)
DK (1) DK2265580T3 (enExample)
EA (1) EA017929B1 (enExample)
ES (1) ES2370592T3 (enExample)
IL (1) IL207995A (enExample)
MX (1) MX2010010015A (enExample)
NZ (1) NZ587824A (enExample)
PL (1) PL2265580T3 (enExample)
PT (1) PT2265580E (enExample)
SI (1) SI2265580T1 (enExample)
UA (1) UA102091C2 (enExample)
WO (1) WO2009112529A1 (enExample)
ZA (1) ZA201006422B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
JP2019511544A (ja) 2016-04-14 2019-04-25 ４エスツェー アクチェンゲゼルシャフト アジア人患者におけるレスミノスタットの医薬用途
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039404A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
CN101137623A (zh) * 2005-03-15 2008-03-05 尼科梅德有限责任公司 N-磺酰基吡咯及其作为组蛋白脱乙酰酶抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
KR100236806B1 (ko) 1991-12-10 2000-01-15 시오노 요시히코 방향족 설폰아미드계 하이드록삼산 유도체
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP1725528B1 (en) 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
KR101314158B1 (ko) 2005-09-21 2013-10-04 4에스체 악티엔게젤샤프트 히스톤 탈아세틸 효소 억제제로서의 설포닐피롤 염산염

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137623A (zh) * 2005-03-15 2008-03-05 尼科梅德有限责任公司 N-磺酰基吡咯及其作为组蛋白脱乙酰酶抑制剂的用途
WO2007039404A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OJIKA M等.Structure and Synthesis of Reductiline, a novel metabolite from a variant of Streptomyces Orientals..《TETRAHEDRON LETT.》.1982,第23卷(第47期),第4977-4980页. *

Also Published As

Publication number Publication date
UA102091C2 (ru) 2013-06-10
AU2009224623C1 (en) 2014-01-23
ZA201006422B (en) 2011-10-26
CA2719074C (en) 2017-01-17
CA2719074A1 (en) 2009-09-17
US8785659B2 (en) 2014-07-22
DK2265580T3 (da) 2011-10-31
KR101571915B1 (ko) 2015-11-25
CY1111994T1 (el) 2015-11-04
EP2265580B1 (en) 2011-08-10
HK1150319A1 (en) 2011-11-25
ES2370592T3 (es) 2011-12-20
BRPI0909752B8 (pt) 2021-05-25
EA201001270A1 (ru) 2011-04-29
KR20100121656A (ko) 2010-11-18
PL2265580T3 (pl) 2012-01-31
EP2100878A1 (en) 2009-09-16
US20110105568A1 (en) 2011-05-05
CN101970404A (zh) 2011-02-09
AU2009224623A1 (en) 2009-09-17
BRPI0909752B1 (pt) 2020-11-24
SI2265580T1 (sl) 2011-12-30
ATE519739T1 (de) 2011-08-15
NZ587824A (en) 2012-05-25
IL207995A0 (en) 2010-12-30
BRPI0909752A2 (pt) 2015-10-06
WO2009112529A1 (en) 2009-09-17
EP2265580A1 (en) 2010-12-29
MX2010010015A (es) 2011-04-05
EA017929B1 (ru) 2013-04-30
JP2011513467A (ja) 2011-04-28
IL207995A (en) 2013-04-30
PT2265580E (pt) 2011-11-21
AU2009224623B2 (en) 2013-07-18
JP5530939B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
EP3088397B1 (en) Compounds that abrogate the cell cycle g2 checkpoint for use in the treatment of cancer
EA012451B1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
CN108101890A (zh) N-磺酰基吡咯衍生物
KR20170095964A (ko) Hdac1/2 억제제로서 피페리딘 유도체
CN101970404B (zh) 制备作为hdac抑制剂的磺酰基吡咯的方法
WO2013170757A1 (zh) 4-氨基喹唑啉异羟肟酸类化合物及作为抗肿瘤药物应用
WO2025247412A1 (zh) 一种苯基噻唑胺类PI4KIII β/HDAC双靶抑制剂、制备方法及其药物组合物和应用
KR102507397B1 (ko) 히스톤 탈아세틸화효소 억제 활성을 갖는 신규 화합물 및 이의 용도
KR101900574B1 (ko) 신규한 n-히드록시벤즈아미드 및 이의 용도
WO2017011408A1 (en) Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same
KR101900575B1 (ko) 신규한 히드록삼산 및 이의 용도
HK1150319B (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
Calder et al. The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat
CN121263411A (zh) Gspt1降解剂化合物
JP2023510947A (ja) Ｈｄａｃ分解剤
Bhaumik et al. Synthesis, characterization and in vitro and in vivo evaluation of anti-inflammatory activity of some novel 4-thiazolidinone derivatives
KR20180136323A (ko) 히스톤 탈아세틸화 효소 억제 활성을 갖는 신규한 3-치환-2-옥소인돌린 기반 히드록삼산 화합물
WO2016025637A1 (en) Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
HK1186736B (en) (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-pyrrol-3-yl}-acrylamide tosylate salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant